


Tivnan

Resistance to Targeted Therapies Against Adult Brain Cancers

This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.

This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies.



160,49 €

149,99 € (zzgl. MwSt.)

Lieferfrist: bis zu 10 Tage

Artikelnummer: 9783319465043

Medium: Buch

ISBN: 978-3-319-46504-3

Verlag: Springer International Publishing

Erscheinungstermin: 16.12.2016

Sprache(n): Englisch

Auflage: 1. Auflage 2016

Serie: Resistance to Targeted Anti-Cancer Therapeutics

Produktform: Gebunden

Gewicht: 5384 g

Seiten: 260

Format (B x H): 160 x 241 mm

